Instrument Inactif

Communiqués Neos Therapeutics, Inc.

Actions

NEOS

US64052L1061

Produits pharmaceutiques

Communiqués

22/03/21	NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements (form 8-K)	AQ
22/03/21	Neos Therapeutics : Aytu BioScience Announces Close of Merger with Neos Therapeutics	PU
12/03/21	Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	GL
10/03/21	Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	GL
10/02/21	Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021	GL
08/02/21	NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
11/01/21	NEOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
04/01/21	Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference	GL
30/12/20	NEOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	AQ
11/12/20	NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
10/12/20	NEOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
10/12/20	Neos Therapeutics : Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company	AQ
09/11/20	NEOS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
09/11/20	Neos Therapeutics: 3Q Earnings Snapshot	AQ
09/11/20	Neos Therapeutics : Reports Third Quarter 2020 Financial Results	AQ
09/11/20	Neos Therapeutics Reports Third Quarter 2020 Financial Results	GL
02/11/20	Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020	GL
02/11/20	Neos Therapeutics : to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020	AQ
09/09/20	Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference	GL
09/09/20	Neos Therapeutics : to Present at Cantor Virtual Global Healthcare Conference	AQ
10/08/20	NEOS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
10/08/20	Neos Therapeutics: 2Q Earnings Snapshot	AQ
10/08/20	Neos Therapeutics Reports Second Quarter 2020 Financial Results	GL
03/08/20	Neos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020	GL
19/06/20	NEOS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ